Home Banking & Finance Avon earnings plunge, profit for Regeneron, Jarden earnings double

Avon earnings plunge, profit for Regeneron, Jarden earnings double

SHARE

High costs sank Avon’s earnings, while sales of Regeneron’s treatment for macular degeneration returned the company to profitability.

This content is for Westfair Online members only. Please to view this content. Become a member by Registering Here.
Print Friendly, PDF & Email

Comments are closed.